245 related articles for article (PubMed ID: 26310546)
1. Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder.
Ciftci S; Ozkurkcugil C; Yilmaz H; Ustuner M; Yavuz U; Yuksekkaya M; Cekmen MB
Int Urogynecol J; 2016 Feb; 27(2):275-80. PubMed ID: 26310546
[TBL] [Abstract][Full Text] [Related]
2. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
Liu HT; Lin H; Kuo HC
Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
[TBL] [Abstract][Full Text] [Related]
3. Urinary nerve growth factor in children with overactive bladder: a promising, noninvasive and objective biomarker.
Oktar T; Kocak T; Oner-Iyidogan Y; Erdem S; Seyithanoglu M; Ziylan O; Kocak H
J Pediatr Urol; 2013 Oct; 9(5):617-21. PubMed ID: 22789557
[TBL] [Abstract][Full Text] [Related]
4. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
Kim SR; Moon YJ; Kim SK; Bai SW
Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
[TBL] [Abstract][Full Text] [Related]
5. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
Liu HT; Chancellor MB; Kuo HC
BJU Int; 2009 Jun; 103(12):1668-72. PubMed ID: 19220267
[TBL] [Abstract][Full Text] [Related]
6. Solifenacin and Tamsulosin Combination Therapy Decreases Urine Nerve Growth Factor/Creatinine Levels in Men.
Chan R; Munoz A; Wenker EP; Whipple M; Miles B; Boone TB
Urology; 2016 May; 91():150-3. PubMed ID: 26829718
[TBL] [Abstract][Full Text] [Related]
7. Urinary Nerve Growth Factor Can Predict Therapeutic Efficacy in Children With Overactive Bladder.
Fukui S; Aoki K; Morizawa Y; Miyake M; Fujimoto K
Urology; 2017 May; 103():214-217. PubMed ID: 28161379
[TBL] [Abstract][Full Text] [Related]
8. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment.
Liu HT; Kuo HC
Urology; 2008 Jul; 72(1):104-8; discussion 108. PubMed ID: 18400272
[TBL] [Abstract][Full Text] [Related]
9. Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder.
Hsiao SM; Chang TC; Chen CH; Wu WY; Lin HH
Menopause; 2017 Jan; 24(1):100-104. PubMed ID: 27648660
[TBL] [Abstract][Full Text] [Related]
10. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention.
Liu HT; Kuo HC
Neurourol Urodyn; 2009; 28(1):78-81. PubMed ID: 19089891
[TBL] [Abstract][Full Text] [Related]
11. The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment?
Alkis O; Zumrutbas AE; Toktas C; Aybek H; Aybek Z
Neurourol Urodyn; 2017 Feb; 36(2):390-393. PubMed ID: 26661444
[TBL] [Abstract][Full Text] [Related]
12. Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial.
Aydoğmuş Y; Sunay M; Arslan H; Aydın A; Adiloğlu AK; Şahin H
Urol Int; 2014; 93(4):437-43. PubMed ID: 25033919
[TBL] [Abstract][Full Text] [Related]
13. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
Liu HT; Chancellor MB; Kuo HC
Eur Urol; 2009 Oct; 56(4):700-6. PubMed ID: 18472208
[TBL] [Abstract][Full Text] [Related]
14. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
Seth JH; Sahai A; Khan MS; van der Aa F; de Ridder D; Panicker JN; Dasgupta P; Fowler CJ
BJU Int; 2013 Mar; 111(3):372-80. PubMed ID: 23444927
[TBL] [Abstract][Full Text] [Related]
15. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder.
Wang LW; Han XM; Chen CH; Ma Y; Hai B
Int Urol Nephrol; 2014 Feb; 46(2):341-7. PubMed ID: 23982767
[TBL] [Abstract][Full Text] [Related]
16. Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis.
Sheng W; Zhang H; Ruth KH
Neurourol Urodyn; 2017 Sep; 36(7):1703-1710. PubMed ID: 28102552
[TBL] [Abstract][Full Text] [Related]
17. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
[TBL] [Abstract][Full Text] [Related]
18. Could urinary nerve growth factor and bladder wall thickness predict the treatment outcome of children with overactive bladder?
Huseynov A; Telli O; Haciyev P; Okutucu TM; Akinci A; Ozkidik M; Erguder I; Fitoz S; Burgu B; Soygur T
Int Braz J Urol; 2022; 48(3):553-560. PubMed ID: 35373950
[TBL] [Abstract][Full Text] [Related]
19. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder.
Yokoyama T; Kumon H; Nagai A
Neurourol Urodyn; 2008; 27(5):417-20. PubMed ID: 17924444
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment.
Chua ME; See MC; Esmeňa EB; Balingit JC; Morales ML
Low Urin Tract Symptoms; 2018 May; 10(2):135-142. PubMed ID: 28150436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]